Maura Gillison, M.D., Ph.D., head and neck medical oncologist and molecular epidemiologist was the first to make the association of human papillomavirus (HPV) and oral cancer. She is the leading expert on HPV and oral cancer. OCF has been privileged to have her as a science advisory board member for over a dozen years, and has been a financial co-sponsor of her work elucidating the role of HPV in the world of oral cancers. Gillison’s work has had, and will continue to have, significant public health implications. In OCF’s view, Dr. Gillison has been insightful, visionary, and with her insatiable scientific drive to find answers, prolific in the body of work produced which has significantly advanced our knowledge of this virus and the disease that it causes.
Recruited from Johns Hopkins, she arrived at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute in 2009 with NCI R01 funding and has added depth to both the Viral Oncology Program and the Cancer Control Program. In 2017 Dr. Gillison was recruited by MD Anderson Cancer Center Dr. Gillison has made significant research contributions to the fields of tumor virology, cancer biology and epidemiology. In 2000, she pioneered a study that provided convincing molecular evidence for HPV16 to be the causative agent of a defined subset of oral cavity cancers, which turned out to be a unique disease etiology in many respects, and that it occurred primarily in the posterior of the oral cavity known as the oropharynx. Anatomically this included the base of tongue, tonsils and the oropharynx itself. She was the first to demonstrate that some of these head and neck squamous cell carcinomas (HNSCCs) were HPV(+). She also characterized the HPV types and anatomical tissue localizations favored by the virus. Her findings have confirmed and extended previous molecular and epidemiological studies, and for the first time, demonstrated that HPV(+) HNSCCs comprise a distinct clinical, pathological disease at the molecular level that are causally associated with persistent high risk HPV16 infection. She has followed that work with additional peer reviewed publications that elucidated populations at risk for this disease etiology, mechanisms of transfer of the virus, and much more.
Dr. Gillison presented data at the ASCO conference in 2009 showing that HPV is the most important predictor of clinical response to tumor therapy and prognosis for patients with these cancers. As a result of this data, the National Cancer Institute has recommended that all clinical trials involving head and neck cancer be stratified by tumor HPV status. As a result of her work identifying a clear survival advantage to HPV+ cancers, the NCI task force on head and neck cancer has approved moving forward with a de-escalation of therapy clinical trial for “favorable” risk HPV-positive oropharyngeal cancers under RTOG with Drs. Andrew Troti (Moffitt) and Gillison as lead investigators. The objective of this study is to validate decreasing the most harmful portions of the treatments to reduce long-term morbidity of therapy without compromising survival. This will be the first de-intensification trial done for oral/head and neck cancer patients.
General Research Interest
Head and neck cancer, human papillomavirus, infectious-disease tumor associations.
Research Description and Evolution
The Gillison laboratory combines the tools of both molecular biology and epidemiology to investigate associations between infectious disease and human tumors. Research to date has focused on the relationship between human papillomavirus (HPV) and head and neck squamous cell carcinoma. The research team has defined the distinct clinical, pathological and molecular characteristics of HPV-associated head and neck cancer; identified the principal risk factors for the disease; validated methods for oral HPV detection; performed proof of concept studies for use of oral HPV detection in oral cancer screening; established tumor HPV status as a major determinant of head and neck cancer prognosis; validated diagnostic methods; and completed HPV-specific therapeutic vaccine trials. The group now leads clinical trials of vaccines for prevention of oral HPV infection, natural history studies of oral HPV infection, population-based surveys of infection, population-based studies of cancer incidence trends over time, and national, clinical trials specific for HPV-associated head and neck cancer. Molecular studies now focus on predictors of response to treatment. The laboratory also has ongoing studies investigating other, possible infectious disease-tumor associations. The principal focus of Dr. Gillison and her laboratory has been until recently to investigate the role of human papillomavirus infection in head and neck malignancies, from cohort studies of oral HPV infection, to genetic indicators of response to chemoradiotherapy. Additionally, Gillison established the gold standard of HPV diagnostic tests, currently in use within clinics nationwide; work which was funded by the Oral Cancer Foundation, and done in collaboration with another OCF science advisory board member, Dr. Mark Lingen, at the University of Illinois, Chicago. Her current work is in the field of immuno therapeutics and she was a lead researcher on the Checkmate 141 trial that brought the drug nivolumab to the world of head and neck cancer treatment. OCF was a financial contributor to that pivotal trial as well. Today that drug is extending lives that previously because of their advanced nature, either failing primary treatment or in a recurrence, had little hope.
The Gillison laboratory has several ongoing collaborations with the Centers for Disease Control, USA, the National Cancer Institute, USA, and the International Agency for Research on Cancer. Dr. Gillison is also a member of the head and neck steering committees of the Radiation Therapy Oncology Group and the Eastern Cooperative Oncology Group. She has published extensively in journals such as
The New England Journal of Medicine, Journal of The National Cancer Institute and the Journal of Clinical Oncology
Maura L. Gillison, M.D., Ph.D., Receives AACR’s Richard and Hinda Rosenthal Memorial Award: View Online
Appointments of Note
In 2016 Dr. Gillison was elected to the National Academy of Medicine, National Academy of Sciences. This is an extraordinary achievement given that its very few members have all been selected for their outstanding achievements in the advancement of scientific knowledge. The membership includes individuals who over the years have won 500 Nobel prizes. Please see more about this exclusive organization and this appointment here
- Unger ERPrevalence of Cervical and Oral Human Papillomavirus Infections Among US Women.J Infect Dis 1/10/2014
- Sanjosé SdComprehensive control of human papillomavirus infections and related diseases.Vaccine 31 Suppl 7 H1-H31 12/31/2013
- Sanjosé SdComprehensive control of human papillomavirus infections and related diseases.Vaccine 31 Suppl 6 G1-G31 12/30/2013
- Sanjosé SdComprehensive control of human papillomavirus infections and related diseases.Vaccine 31 Suppl 5 F1-F31 12/29/2013
- Akagi K, Li J, Broutian TR, Padilla-Nash H, Xiao W, Jiang B, Rocco JW, Teknos TN, Kumar B, Wangsa D, He D, Ried T, Symer DE, Gillison MLGenome-wide analysis of HPV integration in human cancers reveals recurrent, focal genomic instability.Genome Res 12/20/2013
- Chaturvedi AK, Anderson WF, Lortet-Tieulent J, Curado MP, Ferlay J, Franceschi S, Rosenberg PS, Bray F, Gillison MLWorldwide trends in incidence rates for oral cavity and oropharyngeal cancers.J Clin Oncol 31 4550-9 12/20/2013
- Sanjosé SdComprehensive control of human papillomavirus infections and related diseases.Vaccine 31 Suppl 8 I1-31 11/22/2013
- Perez-Ordoñez B, Irish JC, Yu ES, Gillison MLHuman papillomavirus-16 associated adenocarcinoma NOS of base of tongue.Head Neck Pathol 7(3) 268-73 9/1/2013
- Pfister DG, Ang KK, Brizel DM, Burtness BA, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL Jr, Hitchcock YJ, Kies MS, Lydiatt WM, Maghami E, Martins R, McCaffrey T, Mittal BB, Pinto HA, Ridge JA, Samant S, Schuller DE, Shah JP, Spencer S, Weber RS, Wolf GT, Worden F, Yom SS, McMillian NR, Hughes MHead and neck cancers, version 2.2013. Featured updates to the NCCN guidelines.J Natl Compr Canc Netw 11(8) 917-23 8/1/2013M
- Beachler DC, D’Souza G, Sugar EA, Xiao W, Gillison MLNatural history of anal vs oral HPV infection in HIV-infected men and women.J Infect Dis 208(2) 330-9 7/15/2013
- Gillison ML, Castellsagué X, Chaturvedi A, Goodman MT, Snijders P, Tommasino M, Arbyn M, Franceschi SEurogin Roadmap: Comparative epidemiology of HPV infection and associated cancers of the head and neck and cervix.Int J Cancer 134(3) 497-507 2/1/2013
- Lingen MW, Xiao W, Schmidt A, Jiang B, Pickard R, Kreinbrink P, Perez-Ordonez B, Jordan RC, Gillison MLLow etiologic fraction for high-risk human papillomavirus in oral cavity squamous cell carcinomas.Oral Oncol 49(1) 1-8 1/1/2013
- Schwartz S, Alemany L, Snijders PJ, Chaturvedi A, Steinberg BM, , Castellsagué XHuman papillomavirus and diseases of the upper airway: head and neck cancer and respiratory papillomatosis.Vaccine 30 Suppl 5 F34-54 11/20/2012
- Hoskins EE, Morreale RJ, Werner SP, Higginbotham JM, Laimins LA, Lambert PF, Brown DR, Gillison ML, Nuovo GJ, Witte DP, Kim MO, Davies SM, Mehta PA, Kovacic MB, Wikenheiser-Brokamp KA, Wells SIThe fanconi anemia pathway limits human papillomavirus replication.J Virol 86(15) 8131-8 8/1/2012
- Pickard RK, Xiao W, Broutian TR, He X, Gillison MLThe prevalence and incidence of oral human papillomavirus infection among young men and women, aged 18-30 years.Sex Transm Dis 39(7) 559-66 7/1/2012
- Jordan RC, Lingen MW, Perez-Ordonez B, He X, Pickard R, Koluder M, Jiang B, Wakely P, Xiao W, Gillison MLValidation of methods for oropharyngeal cancer HPV status determination in US cooperative group trials.Am J Surg Pathol 36(7) 945-54 7/1/2012
- Gillison ML, Zhang Q, Jordan R, Xiao W, Westra WH, Trotti A, Spencer S, Harris J, Chung CH, Ang KKTobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer.J Clin Oncol 30(17) 2102-11 6/10/2012
- Gilbert J, Rudek MA, Higgins MJ, Zhao M, Bienvenu S, Tsottles N, Wahl RL, Forastiere AA, Gillison MLA phase I trial of erlotinib and concurrent chemoradiotherapy for stage III and IV (M0) squamous cell carcinoma of the head and neck.Clin Cancer Res 18(6) 1735-42 3/15/2012
- Pfister DG, Ang KK, Brizel DM, Burtness B, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL Jr, Hitchcock YJ, Kies MS, Lydiatt WM, Maghami E, Martins R, McCaffrey T, Mittal BB, Pinto HA, Ridge JA, Samant S, Sanguineti G, Schuller DE, Shah JP, Spencer S, Trotti A 3rd, Weber RS, Wolf G, Worden FMucosal melanoma of the head and neck.J Natl Compr Canc Netw 10(3) 320-38 3/1/2012
- Gillison ML, Broutian T, Pickard RK, Tong ZY, Xiao W, Kahle L, Graubard BI, Chaturvedi AKPrevalence of oral HPV infection in the United States, 2009-2010.JAMA 307(7) 693-703 2/15/2012